Voyager Capital Surpluse from 2010 to 2025

VYGR Stock  USD 4.23  0.15  3.42%   
Voyager Therapeutics Capital Surpluse yearly trend continues to be relatively stable with very little volatility. Capital Surpluse is likely to drop to about 384.1 M. During the period from 2010 to 2025, Voyager Therapeutics Capital Surpluse destribution of quarterly values had range of 301.5 M from its regression line and mean deviation of  99,961,996. View All Fundamentals
 
Capital Surpluse  
First Reported
2016-03-31
Previous Quarter
486.5 M
Current Value
490.8 M
Quarterly Volatility
93.4 M
 
Yuan Drop
 
Covid
Check Voyager Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Voyager Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Selling General Administrative of 26 M or Gross Profit of 296.5 M, as well as many indicators such as Price To Sales Ratio of 1.59, Dividend Yield of 0.0 or PTB Ratio of 1.68. Voyager financial statements analysis is a perfect complement when working with Voyager Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Voyager Therapeutics Correlation against competitors.
To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.

Latest Voyager Therapeutics' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Voyager Therapeutics over the last few years. It is Voyager Therapeutics' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Voyager Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Voyager Capital Surpluse Regression Statistics

Arithmetic Mean327,889,774
Geometric Mean310,559,697
Coefficient Of Variation33.85
Mean Deviation99,961,996
Median315,598,000
Standard Deviation110,980,993
Sample Variance12316.8T
Range301.5M
R-Value0.90
Mean Square Error2512.3T
R-Squared0.81
Slope20,974,750
Total Sum of Squares184751.7T

Voyager Capital Surpluse History

2025384.1 M
2024520.6 M
2022452.7 M
2021442.3 M
2020430.3 M
2019412.2 M
2018315.6 M

About Voyager Therapeutics Financial Statements

Voyager Therapeutics shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Voyager Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Voyager Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Voyager Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse520.6 M384.1 M

Pair Trading with Voyager Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Voyager Stock

  0.63MRK Merck CompanyPairCorr

Moving against Voyager Stock

  0.51DRTSW Alpha Tau MedicalPairCorr
  0.35GILD Gilead SciencesPairCorr
The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.
The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Voyager Stock Analysis

When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.